BioNxt Solutions Inc.
BNXTF
$0.46
$0.024.07%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -62.78% | -30.40% | -89.14% | -92.83% | -89.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -62.78% | -30.40% | -89.14% | -92.83% | -89.29% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -62.78% | -30.40% | -89.14% | -92.83% | -83.03% |
| SG&A Expenses | 37.13% | 42.26% | -9.12% | -26.84% | -26.02% |
| Depreciation & Amortization | -74.39% | -66.54% | -63.59% | -53.79% | -45.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.21% | 0.42% | -27.35% | -34.33% | -20.06% |
| Operating Income | 4.76% | -0.60% | 25.34% | 30.90% | 15.79% |
| Income Before Tax | 6.18% | 7.52% | 28.15% | 31.03% | 50.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.53% | 8.87% | 29.26% | 32.15% | 48.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.53% | 8.87% | 29.26% | 32.15% | 48.92% |
| EBIT | 4.76% | -0.60% | 25.34% | 30.90% | 15.79% |
| EBITDA | 4.36% | -1.29% | 25.10% | 30.52% | 14.95% |
| EPS Basic | 13.21% | 16.22% | 35.88% | 39.20% | 55.92% |
| Normalized Basic EPS | 9.62% | 12.36% | 33.43% | 35.36% | 25.93% |
| EPS Diluted | 13.21% | 16.22% | 35.88% | 39.20% | 55.92% |
| Normalized Diluted EPS | 9.62% | 12.36% | 33.43% | 35.36% | 25.93% |
| Average Basic Shares Outstanding | 5.76% | 8.21% | 9.66% | 12.30% | 14.45% |
| Average Diluted Shares Outstanding | 5.76% | 8.21% | 9.66% | 12.30% | 14.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |